NEFL and early-onset autosomal dominant Alzheimer disease: Higher levels of serum NfL are considered a marker for central-peripheral distal axonopathy disease and are correlated with more severe neurological damage and worse clinical outcomes in patients with conditions such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease (18).